Author: Abhay Panchal

Healthcare experts at AIMed26 discussed how liability and accountability should be handled when artificial intelligence (AI) tools make mistakes. Panelists noted that clinicians and hospitals currently face much of the potential liability when an AI-generated recommendation contributes to harm, while developers may face less direct accountability. MIT researcher Leo Anthony Celi argued that responsibility should be shared among clinicians, healthcare organizations and developers, based on what each party knew and controlled. However, experts said legal accountability will likely evolve through court decisions as real-world cases emerge.

Read More

Ascension reported a 399.4% year-over-year increase in outpatient surgery visits during the first quarter of fiscal 2027, largely reflecting its acquisition of AMSURG, which contributed approximately 283,000 surgical visits. Excluding the acquisition, outpatient surgery volume still increased 3.6% compared with the same quarter in fiscal 2026, indicating underlying growth in ambulatory procedures. Ascension completed its $3.9 billion AMSURG acquisition in June 2026, adding approximately 250 ambulatory surgery centers (ASCs) to its existing network of around 50. The transaction followed an agreement to divest seven centers to address Federal Trade Commission antitrust concerns. AMSURG has also continued expanding its portfolio through…

Read More

The Centers for Medicare & Medicaid Services (CMS) has finalized a higher hospital outpatient payment classification for Gastric Alimetry testing, increasing the national unadjusted Medicare payment to $1,048.77 in 2027. Effective January 1, 2027, CPT code 0868T will move from Ambulatory Payment Classification (APC) 5723 (Level 3) to APC 5724 (Level 4 Diagnostic Tests and Related Services). The new rate is approximately 2.4 times the previous Level 3 payment. CMS cited hospital cost data, public comments and recommendations from its Advisory Panel on Hospital Outpatient Payment. The change is a payment classification decision, not a Medicare coverage determination; existing coverage…

Read More

South Korean medical robotics startup MedInTech has raised $25.7 million in Series C financing to expand its AI-powered robotic endoscopy portfolio and accelerate development of therapeutic and surgical technologies. The round was jointly led by existing investor Atinum Investment and new investor KB Investment, bringing the company’s cumulative funding to approximately $47.3 million. The capital will support research and development, regulatory approvals, manufacturing capacity and international commercialization. MedInTech’s flagship product, INTION S, uses motor-driven controls and AI-based image recognition to support endoscope navigation and autonomous steering. A clinical trial involving 178 adults at Seoul National University Hospital compared the system…

Read More

A prospective, single-center study published in the Journal of Clinical Medicine evaluated AI-assisted lesion detection and disease-specific optical classification during surveillance colonoscopy in patients with ulcerative colitis (UC). The study included 82 adults undergoing three sequential colonoscope withdrawals using high-definition white-light imaging (WLI), linked-colour imaging (LCI), and LCI with Fujifilm’s CAD-EYE AI detection system activated. Among 54 patients with identified lesions, researchers found 281 lesions, including 22 neoplastic lesions in 19 patients. Most neoplastic lesions were low-grade dysplasia; one was high-grade dysplasia, and no adenocarcinomas were identified. The overall lesion miss rate was 5.7% with WLI, 2.5% with LCI and…

Read More

Colorectal cancer has become the deadliest cancer among Americans under 50, with diagnoses rising since the mid-1990s even as rates among older adults decline. The trend is also being reported internationally, with people born in the 1990s facing at least four times the risk of developing colorectal cancer compared with those born in the 1960s in countries including Australia, Canada and England. Although screening guidelines in the US were lowered to age 45 in 2021, researchers say the reasons behind the increase remain unclear. Delayed diagnosis may contribute, but experts suspect additional biological and environmental factors. Several research directions are…

Read More

In a NEJM perspective titled “What the Robot Still Can’t Do,” physician Shantanu Nundy describes how an AI chatbot helped identify functional dyspepsia in a patient with nearly a decade of unexplained abdominal symptoms. The patient had previously undergone a negative H. pylori test and normal upper endoscopy, with no improvement after a trial of omeprazole. The AI model identified functional dyspepsia as the leading consideration and suggested other possible diagnoses. The physician used this input alongside his clinical assessment to make a presumptive diagnosis and initiate amitriptyline treatment after discussing uncertainty and potential risks with the patient. At a…

Read More

Geneoscopy and Exact Sciences have reached a settlement resolving all pending district court litigation in Delaware concerning Geneoscopy’s ColoSense colorectal cancer screening test. The court dismissed all claims and counterclaims, including Exact Sciences’ patent infringement claims and allegations of false or misleading advertising. The settlement includes no admission of liability or wrongdoing by either company, and its financial and other terms remain confidential. The resolution follows several victories for Geneoscopy at the US Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB). In July 2025, the PTAB found all 20 challenged claims of an Exact Sciences patent unpatentable as…

Read More

The FDA has cleared Medtronic’s Hugo robotic-assisted surgery (RAS) system for additional general surgery procedures in the United States, expanding its use beyond urology. The 510(k) clearance covers upper abdominal procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair, and small bowel resection, as well as lower abdominal procedures such as inguinal hernia repair and appendectomy. According to Medtronic, these procedures represent approximately 3.5 million surgeries annually in the US, accounting for more than half of the country’s soft-tissue procedures. The system features a modular design that allows surgical teams to configure the robotic arms according to the procedure and…

Read More

The FDA has granted Fast Track designation to Cardiff Oncology’s investigational drug onvansertib, in combination with FOLFIRI and bevacizumab, for the first-line treatment of adults with KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC). The designation is supported by results from the company’s ongoing randomized Phase 2 CRDF-004 trial. According to the company, the proposed Phase 3 regimen of 30 mg onvansertib achieved a confirmed objective response rate of 72.2%, compared with 42.1% for FOLFIRI and bevacizumab alone in the intent-to-treat population. As of September 28, 2026, median progression-free survival had not been reached in the 30 mg treatment arm, compared…

Read More